Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update – P&T Community

Related Articles:

• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Intec Readying for New Phase 3 Accordion Pill Study in Parkinson’s May 18, 2020 Intec Pharma and its manufacturing partner, Lohman Therapie-Systeme (LTS) have shown an ability to manufacture the Accordion Pill Carbidopa/Levodopa (AP-CD/LD), an investigational Parkinson’s therapy, at a commercial scale, and are advancing with the production of stability lots expected to bring it into a new Phase 3 trial. Meanwhile, Intec is looking for partners for the late-stage development and commercialization of AP-CD/LD. “Our partnering…
• Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update - BioSpace August 9, 2019 Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update  BioSpacePublished: Aug 09, 2019. JERUSALEM, Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial ...
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update - P&T Community May 7, 2019 Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update  P&T CommunityJERUSALEM, May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three ...
• Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update - Yahoo Finance August 9, 2019 Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update  Yahoo FinanceJERUSALEM, Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces financial results for the three and six months ...
• Intec Pharma Ltd (NTEC) Gets a Buy Rating from Oppenheimer - Analyst Ratings March 20, 2019 Intec Pharma Ltd (NTEC) Gets a Buy Rating from Oppenheimer  Analyst RatingsIn a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Intec Pharma Ltd (NTEC – Research Report). The company's shares ...
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update - Yahoo Finance May 7, 2019 Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update  Yahoo FinanceJERUSALEM, May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces financial results for the three months ended ...
• Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
• Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference - P&T Community March 13, 2019 Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference  P&T CommunityJERUSALEM, March 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company's ...
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders - P&T Community June 25, 2019 Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders  P&T CommunityJERUSALEM, June 25, 2019 /PRNewswire/ --- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier ...
• Zscaler, Inc. (ZS) Analysts See $-0.09 EPS; Intec Pharma LTD. – Ordinary Shares (NTEC) Shorts Lowered By 7.91% - The EN Herald May 10, 2019 Zscaler, Inc. (ZS) Analysts See $-0.09 EPS; Intec Pharma LTD. – Ordinary Shares (NTEC) Shorts Lowered By 7.91%  The EN HeraldAnalysts expect Zscaler, Inc. (NASDAQ:ZS) to report $-0.09 EPS on June, 5.They anticipate $0.03 EPS change or 50.00% from last quarter's $-0.06 EPS.
• Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference - PRNewswire April 1, 2019 Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference  PRNewswireJERUSALEM, April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will ...
• Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders - PRNewswire May 2, 2019 Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders  PRNewswireJERUSALEM, May 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the results from a ...
• Intec Pharma Granted Hong Kong Patent for Carbidopa/Levodopa Pill for Parkinson’s July 25, 2017 Hong Kong has issued a patent to Intec Pharma for its investigational Accordion Pill Carbidopa/Levodopa (AP-CD/LD) drug delivery for Parkinson’s disease symptoms in advanced patients. The patent (HK1158545) is titled “Carbidopa/Levodopa Gastroretentive Drug Delivery” and is scheduled to remain active until April 2029. The patent belongs to Intec’s IN-7 patent family that already includes patents in the U.S., European Union, China, Japan, South Africa, and…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders - BioSpace June 19, 2019 Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders  BioSpaceJERUSALEM, June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that results from a ...